Key result
Viability studies are indicated in patients with ischaemic cardiomyopathy and poor left ventricular function (LVEF ≤35%) to guide the choice between medical therapy and revascularization.
Why the study?
Does coronary revascularization improve left ventricular ejection fraction and functional class in patients with ischaemic cardiomyopathy and viable tissue?
Does coronary revascularization improve left ventricular ejection fraction and functional class in patients with ischaemic cardiomyopathy and viable tissue?
Viability studies are indicated in patients with ischaemic cardiomyopathy (LVEF ≤35%) to guide revascularization, which can improve LVEF and functional class in those with viable tissue.
May inform revascularization decisions in ischaemic cardiomyopathy with LVEF ≤35%; leaves open the need for randomized confirmation of functional gains.
In patients with relatively preserved left ventricular function (left ventricular ejection fraction >35%) and symptoms of angina pectoris, interfering with the daily life-style of the patient, coronary revascularization may be indicated without the need of viability studies. It is in the subgroup of patients with poor left ventricular function (ƒ35%) and symptoms of congestive heart failure (ischaemic cardiomyopathy) that viability studies are indicated. The therapeutic options in these patients include medical therapy, revascularization or heart transplantation. The latter option is still restricted due to the relative shortage of donor hearts. Therefore the choice of therapy for the majority of these patients will be either medical therapy or revascularization, particularly since revascularization procedures in these patients are associated with an increased risk of periprocedural complications [12] . But the improvement of both left ventricular ejection fraction [13] and functional class [14] in patients with dysfunctional but viable tissue undergoing revascularization justifies revascularization procedures in these patients.
No takes yet. Share an insight, caveat, or question.
Bax et al. (1998) conducted a review in Ischaemic cardiomyopathy. Viability studies and revascularization vs. Medical therapy was evaluated. Viability studies are indicated in patients with ischaemic cardiomyopathy and poor left ventricular function (LVEF ≤35%) to guide the choice between medical therapy and revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: